Equities

Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Actions
  • Price (USD)12.55
  • Today's Change-0.44 / -3.39%
  • Shares traded329.00
  • 1 Year change19.64%
  • Beta4.9801
Data delayed at least 15 minutes, as of Jun 25 2019 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

  • Revenue in USD (TTM)86.00k
  • Net income in USD-36.75m
  • Incorporated2007
  • Employees25.00
  • Location
    Zynerba Pharmaceuticals Inc80 W. Lancaster Avenue, Suite 300DEVON 19333United StatesUSA
  • Phone+1 (484) 581-7505
  • Fax+1 (302) 655-5049
  • Websitehttp://zynerba.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
American Brivision (Holding) Corp212.24k-4.63m265.41m38.00------1,250.53-0.3759-0.37590.0168-0.32570.0424--0.14575,585.26-94.20------99.29---2,220.40--0.1228-0.6616----------------
Cyclerion Therapeutics Inc0.00-127.35m267.71m140.00---------4.65-4.650.00-0.2829------0.00-----------------------------22.71------
OptiNose Inc10.68m-104.96m274.82m99.00--3.08--26.67-2.58-2.580.26292.240.05160.45742.59107,828.30-50.76---57.64--80.08---983.22--6.74-14.420.4404-------72.12------
Sutro Biopharma Inc41.26m-37.52m277.17m154.00--1.96--6.22-1.66-1.661.825.70------280,646.30-------------90.95------0.0984---25.75---79.38------
Protagonist Therapeutics Inc21.70m-45.37m280.52m62.00--2.70--12.56-1.94-1.940.93734.310.1542--3.75339,125.00-32.23---40.68-------209.02------0.00--54.14---5.32------
Harpoon Therapeutics Inc4.25m-36.06m282.66m50.00--2.17--68.15-1.50-1.500.17675.49------94,466.66-------------848.37------0.00--570.90---62.60------
Zynerba Pharmaceuticals Inc86.00k-36.75m284.93m25.00--4.04--3,193.11-2.27-2.270.00513.230.0013--0.02313,440.00-54.28-58.08-61.75-67.45-----42,734.72-9,603.85----0.00-----38.07-24.67--154.21--
Marker Therapeutics Inc205.99k-147.96m286.55m11.00--4.80--1,384.47-4.41-4.410.01081.310.0061----18,726.36-439.54-443.10-469.72-1,775.94-----71,827.72-109,881.50----0.00-------1,247.26------
Axcella Health Inc-100.00bn-100.00bn290.11m49.00-----------------------------------------------------16.63------
XBiotech Inc0.00-22.93m291.89m56.00--6.98-----0.6395-0.63950.001.020.00----0.00-46.48-50.49-49.10-54.12-----------76.260.00------36.24--15.64--
Rafael Holdings Inc4.74m-1.25m296.01m14.00--2.59913.1264.49-0.0844-0.28730.36288.470.0367--6.72338,785.70-1.07---1.16-------29.16------0.1054---22.20---6,730.44------
CASI Pharmaceuticals Inc0.00-32.05m300.55m124.00--2.88-----0.3522-0.35220.001.090.00----0.00-31.69-52.53-36.58-56.39-------113,527.40---260.980.0119-------155.07--92.33--
Data as of Jun 25 2019. Currency figures normalised to Zynerba Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

18.80%Per cent of shares held by top holders
HolderShares% Held
ETF Managers Group LLCas of 31 May 20192.22m10.55%
The Vanguard Group, Inc.as of 31 Mar 2019538.46k2.56%
BlackRock Fund Advisorsas of 31 Mar 2019294.27k1.40%
Horizons ETFs Management (Canada), Inc.as of 06 Jun 2019194.80k0.93%
Campbell Capital Management, Inc.as of 31 Mar 2019180.79k0.86%
AdvisorShares Investments LLCas of 07 Jun 2019112.04k0.53%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2019111.60k0.53%
Geode Capital Management LLCas of 31 Mar 2019103.48k0.49%
Morgan Stanley Smith Barney LLC (Invt Mgmt)as of 31 Mar 2019102.38k0.49%
Susquehanna Financial Group LLLPas of 31 Mar 201998.70k0.47%
More ▼
Data from 31 Mar 2019 - 20 Jun 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.